Small Molecule Prefilled Syringes Market Stand Out As The Biggest Contributor In Healthcare

The global small molecule prefilled syringes market was valued at US$ 13,749.4 million in 2016 and is expected to witness a robust CAGR of 4.6% over the forecast period (2017–2025).

Manufacturers are engaged in development of dual or multi-chambered prefilled syringes (AL Biosciences, Inc. manufacturers multi-chambered prefilled syringe), which have various applications in areas such as reconstituted drugs and other potent drugs (for instant therapeutic action). These also offer convenience to end users. Furthermore, technological advancements in design and manufacturing of prefilled syringes have also aided pharmaceutical players to commercialize various drugs into prefilled dosage forms such as Penicillin. Several pharmaceutical players have developed prefilled syringes containing active pharmaceutical ingredients, which has aided these players in increasing their revenues. For instance, Teva Pharmaceutical Industries Ltd. earned significant revenues from the sale of its drug Copaxone in 2016, which comes in a prefilled syringe. Manufacturers of prefilled syringe have developed innovative prefilled syringes and dual- and multi-chambered syringes for sensitive drugs to avoid reactions. The drug chamber is separated with diluent chamber with a barrel in between the two chambers and the barrel serves as a barrier between two chambers. For instance, Pfizer, Inc. has iSecure one piece prefilled syringe without needle. iSecure is a one- piece, needle-free technology which helps in minimizing needle-stick injuries.

Get HOLISTIC Request Sample Copy Of This Business Report:
https://www.coherentmarketinsights.com/insight/request-sample/1629

Effectiveness of drug delivery mainly depends on route of administration. Parenteral are highly preferred and commonly used route of drug administration. The recent past has witnessed significant growth in advanced drug delivery devices, due to development and easy availability of parenteral drugs. Main benefits of prefilled syringes over conventional drug delivery systems is improved product safety, self-administration, accurate dosing, and low chances of drug contamination. Self-injection advantage of prefilled syringes is a major factor for increasing adoption of these, thus aiding in growth of the prefilled syringe market globally. Apart from these aforementioned benefits, dual-chamber prefilled syringe may be useful with reconstituted drugs, which would help in avoiding wastage of drugs and overdose. Major pharmaceutical companies are focusing on advancing the use of self-administration devices globally. In 2015, SCHOTT launched a prefillable syringe design—SCHOTT TopPac. These SD polymer prefillable syringes minimize the risk between sensitive drugs and packaging container.

However, factors such as complex manufacturing process, high costs, and requirement of high quality of these products (responsible for high costs) are expected to hinder growth of the market over the forecast period.

Some major players operating in the small molecule prefilled syringes market include Pfizer, Inc., Sanofi S.A., Mylan N.V., Teva Pharmaceutical Industries Ltd., Becton, Dickinson and Company, and Fresenius Kabi AG.

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/1629

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.